Dr. Nicholas Lydon           CML     Chronic myeloid leukemia

''Nicholas B. Lydon is a British scientist and entrepreneur. He won 2009 Lasker Clinical Award for the development of Gleevec, a selective BCR-ABL inhibitor for the treatment of chronic myeloid leukemia (CML). Lydon earned a BS in biochemistry from the University of Leeds, England and received his Ph.D in biochemistry from the University of Dundee, Scotland.''
Extract of http://en.wikipedia.org/wiki/Nicholas_Lydon
ARTICLES
​
" Gleevec: From Bench to Clinic"                            
November 2004, UC Santa Barbara
                                        See the history of CML